Chris Boshoff: Phase 3 results for PROTAC ER degrader in advanced or metastatic breast cancer
Chris Boshoff, Chief Oncology Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“With our partner Arvinas, we have announced positive topline progression-free survival results from a Phase 3 study with our investigational PROTAC ER degrader in patients with ER+/HER2- advanced or metastatic Breast Cancer.
The trial met its primary endpoint in one of the populations studied, patients whose tumors harbor estrogen receptor 1 (ESR1) mutations. Read our press release here.
Patients with ER+/HER2- advanced metastatic breast cancer face significant clinical challenges, with disease progression and resistance limiting their treatment options. ESR1 mutations are a common cause of resistance and are found in approximately 20-40% of advanced, ER+ breast cancers.
This study underscores Pfizer’s longstanding leadership in working to advance scientific innovation for people impacted by breast cancer. Thank you to all of the investigators, Pfizer colleagues, patients and their families for their participation in this important research.”
Proceed to the video attached to the post.
More posts featuring Chris Boshoff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023